Real-world outcomes of pembrolizumab plus carboplatin plus paclitaxel or nab-paclitaxel in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Tabah, Ashley
Huggar, David
Kish, Jonathan
Bapat, Bela
Liassou, Djibril
Gajra, Ajeet
Miller, Talia
Copher, Ronda
Patel, Manali, I
机构：
[1] Bristol Myers Squibb, Summit, NJ USA
[2] Cardinal Hlth, Dublin, OH USA
[3] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[4] Stanford Univ, Sch Med, Stanford, CA 94305 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21717
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naive, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis
    Chen, Yingkai
    Kang, Shizhou
    Yan, Ming
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (03):
  • [42] Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC).
    Hawkins, M. J.
    Georgy, M.
    Makhson, A.
    Cheporov, S.
    Sergey, O.
    Yablonsky, P.
    Bhar, P.
    Socinski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 397S - 397S
  • [43] NAB-PACLITAXEL IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE THERAPY IN DIABETIC PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Hirsh, Vera
    Owen, Scott
    Ko, Amy
    Renschler, Markus F.
    Socinski, Mark A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S584 - S584
  • [44] Effectiveness of nab-paclitaxel for malignant effusion in non-small cell lung cancer
    Iwai, Y.
    Koyama, N.
    Watanabe, Y.
    Miwa, C.
    Nagai, Y.
    Koyama, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Ph I/II Carboplatin, Nab-Paclitaxel and Pembrolizumab for Advanced NSCLC (HCRN LUN13-175): Outcomes by Nab-Paclitaxel Dose
    Gentzler, R.
    Mohindra, N.
    Jalal, S.
    Reckamp, K.
    Hall, R.
    Hanna, N.
    Chae, Y. K.
    Villaflor, V.
    Koczywas, M.
    Helenowski, I.
    Rademaker, A.
    Patel, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S385 - S386
  • [46] Paclitaxel plus carboplatin in advanced non-small-cell lung cancer
    Rosell, R
    Monzó, M
    López-Cabrerizo, MP
    ONCOLOGY-NEW YORK, 1999, 13 (09): : 30 - 34
  • [47] A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin
    Chang, Won Jin
    Sun, Jong-Mu
    Lee, Ji Yean
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Park, Keunchil
    LUNG CANCER, 2014, 84 (01) : 51 - 55
  • [48] nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer
    Lammers, Philip Edward
    Lu, Bo
    Horn, Leora
    Shyr, Yu
    Keedy, Vicki
    ONCOLOGIST, 2015, 20 (05): : 491 - 492
  • [49] nab-Paclitaxel plus Carboplatin for Elderly Patients with Advanced NSCLC (ABOUND.70+)
    Langer, Corey J.
    Amiri, Katayoun I.
    Coleman, Morton
    Haggstrom, Daniel
    Konduri, Katrik
    Sanford, Alexandra
    Skinner, William
    Smith, David
    Socoteanu, Matei
    Trunova, Nataliya
    Weiss, Jared
    Santos, Edgardo
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S551 - S551
  • [50] Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non–small cell lung cancer
    Isamu Okamoto
    Nobuyuki Yamamoto
    Kaoru Kubota
    Yuichiro Ohe
    Naoyuki Nogami
    Haruyasu Murakami
    Hidetoshi Yamaya
    Katsuhiro Ono
    Kazuhiko Nakagawa
    Investigational New Drugs, 2012, 30 : 1132 - 1137
12345